Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial

Frank Vinluan / medcitynews - Eli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study are scheduled for presentation next month during the American Diabetes Ass…

AI Summary: Eli Lilly’s triple‑agonist produced average weight loss exceeding 28% in a pivotal study, positioning the drug as a leader among late‑stage obesity candidates. The results close the gap with surgical outcomes and promise major clinical and commercial impact—assuming regulators are satisfied and long‑term safety and durability data hold up.

• GLP-1 drugs closing gap with bariatric surgery (3)
• GLP-1 mechanisms and potential cancer benefits (3)
• Lilly’s retatrutide trial: 28% weight loss and implications (4)
• All Other Stories

GLP-1 drugs closing gap with bariatric surgery

GLP-1 mechanisms and potential cancer benefits

Lilly’s retatrutide trial: 28% weight loss and implications

All Other Stories